梅州女性怀孕一个月流产(梅州微管打胎技术) (今日更新中)

TAIYUAN, June 18 (Xinhua) -- A Chinese medical university will join hands with the Massey University of New Zealand to set up a community clinic specializing in chronic diseases in north China's Shanxi Province.The community clinic in Taiyuan, the provincial capital city, will provide medical services to more than 7,500 residents in the city's Hanxiguandong community, Ma Qianjin, vice president of the Shanxi University of Traditional Chinese Medicine, said on Friday.Residents will be able to seek advice from both Chinese and New Zealand experts on how to prevent chronic diseases like diabetes, said Ma.The clinic, which is expected to open this year, will also provide residents with free health check-ups and create health records for them.Bruce Ullrich, a Massey University board member, said on Friday that the clinic will integrate Western service with traditional Chinese medical techniques in its prevention and treatment of chronic diseases."The community clinic will mainly focus on people with obesity, diabetes and other chronic diseases. The cost of disease prevention will be dramatically lower than the cost of treatment," said Ullrich.Zhang Xinwei, deputy director of the provincial science and technology bureau, said that if the clinic's practices are successful, the model may be adopted by other regions in China.

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."

STOCKHOLM, July 7 (Xinhua) -- A patient has been given a new trachea made from a synthetic scaffold seeded with his own stem cells in a Stockholm's hospital, the Swedish medical university Karolinska Institutet said on Thursday.The operation was performed on June 9th at Karolinska University Hospital in Huddinge and the patient, a 36-year old man, has been well on the way to recovery and would be discharged from the hospital on Friday, the university said in a statement.The patient had been suffering from late stage tracheal cancer with the tumor had reached approximately 6cm in length and was extending to the main bronchus.Since no suitable donor windpipe was available, the transplantation of the synthetic tissue engineered trachea was performed as the last possible option for the patient.The successful transplantation of tissue engineered synthetic organs, referred to as regenerative medicine, could open promising therapeutic possibilities for the thousands of patients who suffer from similar conditions.Transplantations of tissue engineered windpipes with synthetic scaffolds in combination with the patient's own stem cells as a standard procedure means that patients would not have to wait for a suitable donor organ.This would be a substantial benefit for patients since they could benefit from earlier surgery and have a greater chance of cure, according to the statement.

JERUSALEM, July 25 (Xinhua) -- A new study carried out by a Tel Aviv University researcher indicates that the common backache may not only be caused by bad positions or aging, but also by your genes.Prof. Gregory Livshits of the Sackler Faculty of Medicine says that genes play a major role in back pain, especially in the lower back, and in spinal deterioration.In a decade-long project with 2,500 identical and non-identical twins, Livshits found that, in one Arab family, the same back problems appeared in all the members of the family, whether young or old.According to the study, non-identical twins were three times more likely to have back pain, while identical twins were six times more likely to have the same back problems.Livshits believes the discovery of the link between back pains and genes could lead to much better treatment.The research was developed in collaboration with a team of scientists at Kings College, London, led by Prof. Tim Spector and Dr. Fran Williams and was recently published in the journal " Annals of the Rheumatic Diseases."In order to better investigate the genetic causes for one of the world most common pains, Livshits and his colleagues hope to put together an international consortium of research groups.

来源：资阳报